Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

928 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic value of CD40 in adult soft tissue sarcomas.
Ottaiano A, De Chiara A, Perrone F, Botti G, Fazioli F, De Rosa V, Mozzillo N, Ravo V, Morrica B, Gallo C, Pisano C, Napolitano M, Ascierto PA, Iaffaioli RV, Apice G. Ottaiano A, et al. Among authors: napolitano m. Clin Cancer Res. 2004 Apr 15;10(8):2824-31. doi: 10.1158/1078-0432.ccr-0139-03. Clin Cancer Res. 2004. PMID: 15102691
Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases.
Carta F, Demuro PP, Zanini C, Santona A, Castiglia D, D'Atri S, Ascierto PA, Napolitano M, Cossu A, Tadolini B, Turrini F, Manca A, Sini MC, Palmieri G, Rozzo AC; Italian Melanoma Intergroup. Carta F, et al. Among authors: napolitano m. Melanoma Res. 2005 Aug;15(4):235-44. doi: 10.1097/00008390-200508000-00002. Melanoma Res. 2005. PMID: 16034300
Human melanoma metastases express functional CXCR4.
Scala S, Giuliano P, Ascierto PA, Ieranò C, Franco R, Napolitano M, Ottaiano A, Lombardi ML, Luongo M, Simeone E, Castiglia D, Mauro F, De Michele I, Calemma R, Botti G, Caracò C, Nicoletti G, Satriano RA, Castello G. Scala S, et al. Among authors: napolitano m. Clin Cancer Res. 2006 Apr 15;12(8):2427-33. doi: 10.1158/1078-0432.CCR-05-1940. Clin Cancer Res. 2006. PMID: 16638848
Intermediate dose recombinant interferon-alpha as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon.
Ascierto PA, Daponte A, Parasole R, Perrone F, Caracò C, Melucci M, Palmieri G, Napolitano M, Mozzillo N, Castello G. Ascierto PA, et al. Among authors: napolitano m. Cancer. 2000 Oct 1;89(7):1490-4. doi: 10.1002/1097-0142(20001001)89:7<1490::aid-cncr11>3.0.co;2-v. Cancer. 2000. PMID: 11013362 Clinical Trial.
Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, Capone M, Caracò C, Calemma R, Beneduce G, Cerrone M, De Rosa V, Palmieri G, Castello G, Kirkwood JM, Marincola FM, Mozzillo N. Ascierto PA, et al. Among authors: napolitano m. J Transl Med. 2010 Aug 16;8:76. doi: 10.1186/1479-5876-8-76. J Transl Med. 2010. PMID: 20712892 Free PMC article. Clinical Trial.
928 results